

1 **Title: The novel duodenal isolate *Streptococcus salivarius* AGIRA0003 promotes barrier**
2 **dysfunction and IgG responses in functional dyspepsia.**

3
4 **Authors:** Grace L. Burns^{1,2,3†}, Jasmine A. Wark^{1,2,3†}, Emily C. Hoedt^{1,2,3}, Kyra
5 Minahan^{1,2,3}, Simonne Sherwin^{1,2,3}, Jessica K. Bruce^{1,3}, Yen kai Lim^{4,5}, Jing Jie Teh⁴, M.
6 Fairuz B. Jamaluddin^{1,6}, Wai Sinn Soh^{1,2,3}, Shandelle Caban^{1,2,3}, Sophie Fowler^{1,2,3}, Juhura G.
7 Almazi^{1,7}, Ameha S. Woldu^{1,7}, Matthew D. Dun^{1,7}, Pradeep S. Tanwar^{1,6}, Michael D. E.
8 Potter^{1,3}, Erin R. Shanahan^{8§}, Gerald Holtmann^{5,8,9}, Mark Morrison^{4,5,8}, Nicholas J.
9 Talley^{1,2,3,‡}, Simon Keely^{1,2,3,‡,*}.

10
11 **Affiliations:**

12 ¹College of Health, Medicine and Wellbeing, The University of Newcastle; Callaghan, New
13 South Wales, Australia.

14 ²Immune Health Research Program, Hunter Medical Research Institute; New Lambton
15 Heights, New South Wales, Australia.

16 ³Centre of Research Excellence in Digestive Health, University of Newcastle; Callaghan,
17 New South Wales, Australia.

18 ⁴Frazer Institute, Faculty of Medicine, University of Queensland, Saint Lucia, Queensland,
19 Australia.

20 ⁵Centre of Research Excellence in Digestive Health, University of Queensland, Saint Lucia,
21 Australia.

22 ⁶Gynaecology Oncology Research Group, School of Biomedical Sciences and Pharmacy,
23 University of Newcastle, Newcastle, NSW, 2308, Australia.

24 ⁷Priority Research Centre for Cancer Research, Innovation & Translation, College of Health,
25 Medicine and Wellbeing, Callaghan, New South Wales, Australia.

26 ⁸Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane,
27 Australia

28 ⁹Faculty of Medicine, University of Queensland, Saint Lucia, Queensland, Australia.

29 ^{†,‡} These authors contributed equally to this work

30 [§]Current Address: Charles Perkins Centre, School of Life and Environmental Sciences, The
31 University of Sydney, Sydney, Australia.

32 ^{*}Corresponding author. Email: simon.keely@newcastle.edu.au

33
34 **Acknowledgments:** We gratefully acknowledge the significant contributions of the late Prof.
35 Marjorie M. Walker to the conceptualization, supervision, reviewing, and editing of this
36 manuscript, as well as her profound impact on the fields of DGBI and duodenal pathologies.

37 We thank the Hunter Medical Research Institute Core Histology Facility for processing,
38 sectioning, and scanning histological sections. The authors wish to thank the Department of
39 Gastroenterology at the John Hunter Hospital, New Lambton Heights, Australia and
40 Newcastle Endoscopy Centre, Charlestown, Australia for their support and assistance with
41 the collection of biopsy samples.

42 The authors generously thank Dr. Kurtis Budden (Immune Health Research Program, Hunter
43 Medical Research Institute and University of Newcastle) for providing a stock of *S.*
44 *salivarius* ATCC7073.

45

46 **Funding:**

47 National Health and Medical Research Council Centre for Research Excellence in Digestive
48 Health (MMW, GH, MM, NJT, SK)

49 National Health and Medical Research Council Ideas Grant (SK)

50 National Health and Medical Research Council Investigator Grant (NJT)

51 The Translational Research Institute is supported by a grant from the Australian Federal
52 Government.

53

54 **Author contributions:**

55 Conceptualization: GLB, MM, GH, MMW, NJT, SK

56 Methodology: GLB, JAW, ECH, MM, NJT, SK

57 Investigation: GLB, JAW, ECH, KM, SS, JKB, SF, YL, JTT, MFBJ, WSS, SC, JGA, ASW,
58 MDP, ES

59 Visualization: GLB, JAW

60 Resources: MDD, PST, GH, MM, NJT, SK

61 Writing – original draft: GLB, JAW, SK

62 Writing – review & editing: All authors

63

64 **Competing interests:**

65 GLB: Patent: “Diagnostic marker for functional gastrointestinal disorders” (Australian Patent
66 Application PCT/AU2022/050556) via the University of Newcastle and UniQuest
67 (University of Queensland).

68 GH: Unrestricted educational support from Bayer Ptd, Ltd and the Falk Foundation.
69 Research support was provided via the Princess Alexandra Hospital, Brisbane by GI
70 Therapies Pty Limited, Takeda Development Center Asia, Pty Ltd, Eli Lilly Australia Pty
71 Limited, F. Hoffmann-La Roche Limited, MedImmune Ltd Celgene Pty Limited, Celgene
72 International II Sarl, Gilead Sciences Pty Limited, Quintiles Pty Limited, Vital Food
73 Processors Ltd, Datapharm Australia Pty Ltd Commonwealth Laboratories, Pty Limited,
74 Prometheus Laboratories, Falk GmbH and Co Kg, Nestle Pty Ltd, Mylan. Patent Holder: A
75 biopsy device to take aseptic biopsies (US 20150320407 A1).

76 PST: Listed as an inventor on multiple patents filed by the University of Newcastle and
77 received funding for unrelated projects from EOFBIO, USA. The University of Newcastle
78 holds financial interests in EOF-BIO, USA.

79 MMW: Grant/research support: Prometheus Laboratories Inc (Irritable bowel syndrome
80 [IBS] Diagnostic), Commonwealth Diagnostics International (biomarkers for FGIDs).

81 MM: Patent: “Diagnostic marker for functional gastrointestinal disorders” (Australian Patent
82 Application WO2022256861A1) via the University of Newcastle and UniQuest (University
83 of Queensland). Research grants from Atmo Biosciences, Soho Flordis International (SFI)
84 Australia Research, Bayer Consumer Health, and Yakult-Nature Global Grant for Gut Health;
85 speakers honoraria, and travel sponsorship from Genie Biome, Janssen Australia; consultancy
86 fees from Sanofi Australia and Danone-Nutricia Australia; speaker honoraria and travel
87 sponsorship from Perfect Company (China), and travel sponsorship from Yakult Inc (Japan).

88 MM also acknowledges funding from NHMRC Australia, Australian Research Council,
89 Princess Alexandra Hospital Research Foundation, Medical Research Futures Fund of
90 Australia, Helmsley Charitable Trust via the Australasian Gastrointestinal Research
91 foundation, and United States Department of Defense. MM serves on the science advisory
92 board (non-remunerated) for GenieBiome, Hong Kong. GJH reports to be on the advisory
93 boards Australian Biotherapeutics, Glutagen, Bayer and received research support from
94 Bayer, Abbott, Pfizer, Janssen, Takeda, Allergan. He serves on the Boards of the West
95 Moreton Hospital and Health Service, Queensland, UQ Healthcare, Brisbane and the Gastro-
96 Liga, Germany. He has a patent for the Brisbane aseptic biopsy device and serves as Editor of
97 the Gastro-Liga Newsletter.

98 NJT: Non-financial support from: Norgine (2021)(IBS interest group), personal fees from
99 Allakos (gastroduodenal eosinophilic disease) (2021), Bayer (IBS) (2020), Planet Innovation
100 (Gas capsule IBS) (2020), twoXAR Viscera Labs, (USA 2021) (IBS-diarrhoea), Dr Falk
101 Pharma (2020) (EoE), Sanofi-aventis, Glutagen (2020) (celiac disease), IsoThrive (2021)
102 (esophageal microbiome), BluMaiden (microbiome advisory board) (2021), Rose Pharma
103 (IBS) (2021), Intrinsic Medicine (2022) (human milk oligosaccharide), Comvita Mānuka
104 Honey (2021) (digestive health), Astra Zeneca (2022), outside the submitted work. In
105 addition, Dr. Talley has a patent Nepean Dyspepsia Index (NDI) 1998, Biomarkers of IBS
106 licensed, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to
107 Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional
108 Patent “Microbiota Modulation of BDNF Tissue Repair Pathway” issued, “Diagnostic marker
109 for functional gastrointestinal disorders” Australian Patent Application
110 WO2022256861A1 via the University of Newcastle and UniQuest (University of
111 Queensland). Committees: OzSage; NHMRC Principal Committee (Research Committee)
112 Asia Pacific Association of Medical Journal Editors, Rome V Working Team Member
113 (Gastroduodenal Committee), International Plausibility Project Co-Chair (Rome Foundation
114 funded), COVID-19 vaccine forum member (by invitation only). Community group:
115 Advisory Board, IFFGD (International Foundation for Functional GI Disorders), AusEE.
116 Editorial: Medical Journal of Australia (Editor in Chief), Mayo Clinic Proceedings (Assoc
117 Ed), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University
118 School of Medicine, South Korea, Med (Journal of Cell Press). Dr. Talley is supported by
119 funding from the National Health and Medical Research Council (NHMRC) to the Centre for
120 Research Excellence in Digestive Health and he holds an NHMRC Investigator grant.

121 SK: Patent: “Diagnostic marker for functional gastrointestinal disorders” (Australian Patent
122 Application WO2022256861A1) via the University of Newcastle and UniQuest (University
123 of Queensland). Grants from National Health and Medical Research Council (Ideas Grant and
124 Centre for Research Excellence), grants from Viscera Labs (Research contract), grants from
125 Microba Life Science (Research contract), personal fees from Gossamer Bio, personal fees
126 from Anantara Lifescience, personal fees from Immuron, personal fees from Microba Life
127 Science.

128 JW, ECH, KM, SS, JKB, WSS, SF, SC, JGA, ASW, MDE, ES Authors declare that they
129 have no competing interests.

130 **Data and materials availability:** All data are available in the main text or the supplementary
131 materials, further information is available from the authors upon reasonable request. *S.*
132 *salivarius* AGIRA0003 sequence details can be found in E. C. Hoedt, E. R. Shanahan, S.
133 Keely, A. Shah, G. L. Burns, G. J. Holtmann, N. J. Talley, M. Morrison, Draft Genome
134 Sequence of *Streptococcus salivarius* AGIRA0003, Isolated from Functional Gastrointestinal
135 Disorder Duodenal Tissue. Microbiol Resour Announc 10, e0075821 (2021).

136 **Abstract:**

137

138 Background and aims: Functional dyspepsia (FD) is a highly prevalent disorder of gut-brain
139 interaction (DGBI) that is associated with an altered duodenal microbiota, unexplained low
140 grade duodenal inflammation and altered intestinal permeability. This study aimed to
141 investigate if novel FD-derived bacterial isolates elicited immune responses in FD and the
142 capacity of an immune-stimulating isolate, AGIRA0003 to breach the duodenal epithelial
143 barrier.

144 Methods: Bacterial lysates were investigated for immune reactivity using immunoblotting of
145 patient plasma. Immunoblots were probed with plasma from FD patients (n=44, 46.6±17.5
146 years, 79.6% female) or controls (n=30, 48.9±15.7 years, 63.3% female). Peripheral gut-
147 homing T cells were quantified by flow cytometry and histological analysis used to
148 investigate duodenal biopsies. Polarised Caco-2 cells and FD duodenal spheroids (n=4 lines)
149 were exposed to *Streptococcus salivarius* AGIRA0003 at a multiplicity of infection of 10
150 bacterial cells to 1 mammalian cell for 6 hours.

151 Results: The presence of plasma IgG antibodies against *S. salivarius* AGIRA0003 was
152 significantly associated with FD (χ^2 15.7, 1, $p<0.0001$). Patients with these IgG antibodies
153 had increased gut-homing lymphocytes (0.33±0.77% vs 1.00±1.46%, $p=0.046$). Strain
154 AGIRA0003, but not related commensal strains, disrupted tight junction proteins in Caco-2
155 monolayers, and decreased claudin 1 (CLDN1; 0.49±0.11, $p=0.03$), desmocollin 2 (DSC2;
156 0.64±0.33, $p=0.03$) and desmoglein 2 (DSG2; 0.30±0.12, $p=0.03$) in spheroid monolayers. In
157 addition, DSC2 (2.19±0.97 vs 1.48±0.85, $p=0.02$) and DSG2 (23.22±15.92 vs 12.38±7.34,
158 $p=0.04$) protein levels were decreased in IgG⁺ FD biopsies compared to controls.

159 Conclusions: *S. salivarius* AGIRA0003 is a potential pathobiont capable of impairing
160 duodenal epithelial barrier defences that elicits an immune response in FD patients.

161 Keywords: functional dyspepsia; *Streptococcus salivarius* AGIRA0003; immune activation;

162 host-microbe interaction; duodenum

163

164 **INTRODUCTION**

165
166 Functional dyspepsia (FD) is a disorder of gut-brain interaction (DGBI) characterised by
167 recurrent upper gastrointestinal (GI) symptoms with no structural changes identifiable at
168 endoscopy¹. Given FD is a symptomatic diagnosis, there are no clear biomarkers and
169 diagnosis is often a prolonged process of exclusions. However, FD patients exhibit mucosal
170 “microinflammation”, having greater numbers of duodenal eosinophils², impaired small
171 intestinal barrier integrity and increased mast cell numbers compared to controls^{2,3}. It is
172 thought that microbial and/or dietary antigens interacting with a dysregulated immune system
173 drive FD microinflammation^{4,5}. The role of the duodenum as a major site of antigen
174 sampling⁶ and microinflammation in FD led us to hypothesise that an impaired relationship
175 between the microbiota and immune system would be evident at this site. In that context, FD
176 is associated with compositional changes in the duodenal microbiota, as well as increased
177 bacterial load and altered diversity that can be correlated with meal-related symptoms and
178 reduced quality of life scores^{7,8}. In the FD duodenal mucosa-associated microbiota (d-
179 MAM), *Streptococcus* spp. relative abundance is increased, significantly associated with
180 symptoms^{9,10} and inversely correlated with *Prevotella* relative abundance⁷. In addition,
181 patients have decreased populations of *Prevotella*, *Veillonella* and *Actinomyces*⁸.
182 Collectively, associative studies of the d-MAM and FD symptom profile suggest specific
183 microbial species are associated with homeostatic imbalance and disease initiation in FD.
184
185 Despite these observations, the nature and consequence of duodenal host-microbiota
186 interactions and their relationship to FD symptoms is not well understood. Decreased barrier
187 integrity, which is a feature of FD¹¹, is thought to drive increased translocation of microbes
188 into the mucosa¹¹. This might initiate a humoral response to translocating microbes, and thus
189 explain the mucosal microinflammation observed in FD^{2,12,13}. This hypothesis is supported

190 by our previous work identifying increased intestinal mucosal lymphocytes with a T helper
191 17-like phenotype in FD patients compared to controls¹³, however, causal antigens for such a
192 response have not yet been identified. As such, this study aimed to investigate
193 immunoglobulins specific to novel d-MAM bacterial species cultured from FD patients.
194 Given *Streptococcus* is the dominant reported genus in the FD d-MAM, associated with more
195 severe symptom burden in other studies^{7,9}, we investigated potential interactions between
196 this genus and the immune system in FD. We demonstrate for the first time that FD patients
197 have plasma IgG responses against *S. salivarius* AGIRA0003. Further, this strain has
198 capacity to alter tight junction and desmosome proteins *ex vivo*, suggesting that *S. salivarius*
199 AGIRA0003 may act as a pathobiont in FD, contributing to immune activation in FD.
200

201 **MATERIALS AND METHODS**

202 **Participant selection and recruitment**

203 Participants were recruited from three outpatient gastroenterology clinics (John Hunter,
204 Gosford and Wyong hospitals) in New South Wales, Australia as part of a larger study
205 investigating immune activation in FD^{13, 14}. Patients were diagnosed with FD using the Rome
206 III criteria. Outpatient control participants were recruited from those undergoing a screening
207 endoscopy for iron deficiency anaemia (IDA), a positive faecal occult blot test (FOBT),
208 reflux or dysphagia, who exhibited no abnormal pathology. Exclusion criteria and clinical
209 workup is as previously described^{13, 14}. During endoscopy, biopsies were collected from the
210 second portion of the duodenum (D2) and approximately 36mL of blood was collected in
211 lithium heparin for the isolation of plasma and peripheral blood mononuclear cells
212 (PBMCs)¹³. Plasma samples from healthy community controls, serum samples from 9
213 additional outpatient controls and 10 Crohn's disease (CD) patients with small intestinal
214 inflammation were used from the Digestive Health Biobank (<https://digestivehealth.org.au/>).
215 All work was carried out with approval from the Hunter New England Local Health District
216 Ethics Committee (references 2019/ETH03893, 2020/ETH03303).

217

218 **Culture of bacterial strains**

219 Novel bacterial candidates previously identified through sequencing of the duodenal
220 microbiota in FD compared to controls^{8, 10} were anaerobically isolated from duodenal
221 biopsies, as described¹⁵. All strains were cultured in heart infusion broth supplemented with
222 hemin (10µg/mL) and vitamin K (0.5µg/mL), before genome sequencing was performed¹⁵.
223 Cultures were centrifuged and resuspended in sterile PBS at an optical density (OD)₆₀₀ of
224 ~0.5. Cells were homogenised in Radio ImmunoPrecipitation Assay (RIPA) buffer (Sigma-

225 Aldrich) containing protease and phosphatase inhibitors (HALT cocktail, Thermo Fischer
226 Scientific) to obtain soluble protein lysates.

227

228 Probiotic strains *S. salivarius* M18 and K12 (recovered from a commercially available
229 lozenge from Life Extension Florassist®), *S. salivarius* ATCC7073 (glycerol stock provided
230 from Immune Health Research Program, Hunter Medical Research Institute; GenBank:
231 FJ154807b) and *S. salivarius* AGIRA0003 (GenBank: JAHVCV000000000.1) were
232 inoculated in heart infusion medium supplemented with 7.5% mineral solution 2 and 7.5%
233 mineral solution 3¹⁶, 0.5% yeast extract and 0.1% resazurin (0.1% w/v stock solution) and
234 incubated at 37°C. Growth rates were monitored longitudinally until OD₆₀₀ was 1 for use in
235 cell culture models.

236

237 **Immunoblotting for seroreactive immunoglobulin antibodies**

238 Bacterial lysates were electrophoresed (120v, ~1 hour) using SDS running buffer (1x tris-
239 glycine with 0.1% SDS), on 4-15% polyacrylamide gels (Mini-PROTEAN TGX, BioRad,
240 Hercules, USA). Every second well contained a protein marker. Proteins were then
241 transferred to a polyvinylidene difluoride membrane (90v, 90 mins) and blocked using 2.5%
242 BSA/2.5% skim milk powder (1 hour). Plasma or serum samples (1:500, overnight
243 incubation, 4°C) were used in place of a primary antibody to detect antibodies directed
244 against bacterial proteins, adapted from Lodes *et al*¹⁷. Blots were incubated for 2 hours with
245 anti-human horseradish peroxidase (HRP) secondary antibodies directed against IgG, IgM,
246 IgA or IgE (Sigma-Aldrich) diluted 1:1000 in blocking buffer. Immunoblots were imaged
247 with a ChemiDoc MP System (Bio-Rad, Hercules, USA) and the presence or absence of
248 banding was recorded for each sample. As there was no way to accurately quantify the

249 specific antibody concentration in the plasma samples, given we did not know the identity of
250 the antigen, absolute quantification of the antibody-antigen relationship was not possible.

251

252 **Isolation of seroreactive proteins from total bacterial proteins**

253 Electrophoresis of proteins from bacterial species of interest and a sero-negative control
254 target were conducted as described above. Gel plugs were excised from bands of interest and
255 prepared for liquid chromatography tandem mass spectrometry based on the protocol
256 published by Shevchenko *et al*¹⁸ (**Supplementary methods**). The peptide sequences obtained
257 were initially compared against the *S. salivarius* CCHSS3 sequence (due to sequence
258 availability at the time) and the resulting PROKKA-generated protein coding sequences were
259 then manually compared by NCBI BLASTp to the *S. salivarius* AGIRA0003 strain
260 sequence¹⁵ to identify likely candidates. The complete coding sequence (CDS) for the *S.*
261 *salivarius* AGIRA0003 “GBS Bsp-repeat domain protein” was then used as a query sequence
262 for a BLASTp-based comparison against all non-redundant GenBank CDS translations +
263 PDB + SwissProt + PIR + PRF (excluding environmental samples from whole genome
264 sequencing projects) database curated by the National Centre for Biotechnology Information
265 (NCBI).

266

267 **Caco-2 and duodenal spheroid culture**

268 Polarised Caco-2 monolayers were cultured and maintained as previously described^{19, 20}.
269 Briefly, cells were seeded at a density of 1×10^5 cells/well on Costar Tranwell permeable
270 inserts (pore size 0.4µm polycarbonate membrane, catalogue #3470). Caco-2 monolayers
271 were stimulated in DMEM stimulation media (DMEM high glucose, 1% sodium pyruvate,
272 1% L-glutamine, 10% FCS) in triplicate for 6 hours at 37°C/5% CO₂ with *S. salivarius*
273 strains AGIRA0003, M18, K12 or ATCC7073 at a multiplicity of infection (MOI) of 10, or

274 1µg/mL LPS. Transepithelial electrical resistance (TEER) was measured at baseline and post-
275 stimulation using an EVOM TEER Measurement device and STX2 handheld chopstick
276 electrodes (World Precision Instruments). Basolateral media was sampled, and spot plated
277 onto heart infusion agar plates to investigate translocation.
278 FD derived duodenal spheroids¹⁴ were seeded at a density of 2.5×10^5 cells/well using in-
279 house L-WRN cell-conditioned media as previously described²¹. Spheroids (n=4 lines) were
280 stimulated in DMEM stimulation media with *S. salivarius* AGIRA0003 multiplicity of
281 infection (MOI) 10 or 1µg/mL LPS for 6 hours (37°C/5% CO₂) in duplicate. At 6 hours, cells
282 were collected in RIPA buffer, centrifuged and soluble protein fractions collected and stored
283 at -80°C until use.

284

285 **Tight junction protein immunoblotting**

286 SDS-Page immunoblotting was used to investigate tight junction protein levels in cell culture
287 samples. Protein samples were normalised to 10µg and electrophoresised at 120v for ~1 hour
288 before transfer to a PVDF membrane as above. Blots were blocked in 5% BSA for 1 hour,
289 before incubation (overnight 4°C) with the following antibodies in 5% BSA: zonula
290 occludins 1(ZO-1; Invitrogen #61-7300, 1:2000), desmocollin 2 (DSC2; Abcam ab95967, 1:
291 2500), desmoglein 2 (DSG2; ThermoFisher #PA5-21444, 1:2500), occludin (OCLN;
292 Abclonal A19657, 1:2000), claudin 1 (CLDN1; Invitrogen #51-9000, 1:2000) or β-actin
293 (Abcam #ab8227, 1:10000). Blots were then incubated for 2 hours at room temperature with
294 anti-rabbit IgG HRP secondary antibody (R&D systems HAF008, 1:4000) in 5% BSA and
295 imaged as described above. Protein levels relative to β-actin were determined using ImageJ
296 densitometry analysis and data is presented as fold change to 1.

297

298 **Immunohistochemical staining of duodenal biopsies.**

299 Sodium citrate buffer (pH 6.0) was used for antigen retrieval in FFPE tissues and following
300 blocking with casein, sections were incubated (overnight 4°C) with anti-ZO1 (Invitrogen
301 #61-7300, 1:200), DSG2 (ThermoFisher #PA5-21444, 1:500) or DSC2 (Abcam ab95967,
302 1:200). Slides were then incubated with anti-rabbit secondary antibodies (1:500) conjugated
303 to horseradish peroxidase (HRP). Chromogen 3,3'-Diaminobenzidine (DAB) liquid substrate
304 System (Sigma Aldrich, USA) was used to develop sections, which were counterstained with
305 haematoxylin. Slides were digitalised using Aperio AT2 (Leica Biosystems, Wetzlar,
306 Germany) and the DAB staining intensity in each section was scored using the Halo software
307 area quantification algorithm (Indica Labs USA). The pixel intensity score obtained was used
308 to calculate a H-score: H score = (3x % of pixels with strong stain intensity) + (2x % of
309 pixels with moderate stain intensity) + (1x % of pixels with weak stain intensity), allowing
310 for quantitative staining comparison between groups.

311

312 **Bioinformatic analysis of AGIRA0003 genome**

313 Identification of unique genes for *S. salivarius* AGIRA0003 was performed with EDGAR
314 v3.0²² using NCBI genome deposits for *S. salivarius* M18 (ALIF01000007), *S. salivarius*
315 K12 (AGBV00000000) and *S. salivarius* AGIRA0003 (JAHCV010000078)¹⁵. *S. salivarius*
316 AGIRA0003 singleton amino acid sequences were then blasted against the NCBI
317 refseqprotein database attempt annotation of hypothetical genes.

318

319 **Statistical analysis**

320 Datasets were analysed and graphed using GraphPad Prism 9 software (GraphPad Software
321 Inc., La Jolla, USA). Data was analysed for normality of distribution using the D'Agostino &
322 Pearson test and parametric/nonparametric testing used depending on outcome. Demographic
323 characteristics were analysed by *t* tests. Fisher's exact test was used to analyse co-morbidities

324 and confounders. Relationships between the seroreactive response and FD were analysed by
325 Chi-square testing. Immune parameters and paired cell culture data were evaluated by
326 ordinary one-way ANOVA with Holm-Sidak multiple comparison's test or Kruskal-Wallis
327 test with Dunn's multiple comparisons testing, t tests with Welch's correction or Mann-
328 Whitney t test. Figures are presented as mean \pm SEM, values reported as mean \pm SD, $p < 0.05$ is
329 considered significant.

330 **RESULTS**

331 **Study cohort**

332 Thirty controls (48.9±15.7 years, 63.3% female) and 44 FD patients (46.6±17.5 years, 79.6%
333 female) were included. Seventeen patients had post-prandial distress (PDS) subtype, 7 met
334 the criteria for epigastric pain syndrome (EPS) and 20 had overlapping EPS and PDS
335 (EPS/PDS). Controls included individuals asymptomatic for FD referred for outpatient
336 endoscopy for symptoms of dysphagia (n=6), unexplained IDA; n=8, unexplained and reflux
337 (n=3) or a positive FOBT (n=3). No evidence of organic GI disease was found during
338 endoscopy or clinical histological examination. In addition, n=10 healthy community were
339 also included. Characteristics of the cohort are presented in **Table 1**. As expected, the
340 proportion of FD patients with co-morbid irritable bowel syndrome (IBS) was significantly
341 higher than the controls (3.3% vs 38.6%, $p=0.001$) and proton pump inhibitor (PPI) use was
342 higher in the FD cohort (10.7% vs 40.6%, $p=0.02$).

343

344 ***S. salivarius* AGIRA0003 is associated with a humoral response in FD**

345 We selected the most prominent differentially abundant culturable isolates from an FD
346 biopsy and used immunoblotting to screen participant plasma for interactions¹⁵ (**Figure 1A**).
347 These isolates were taxonomically affiliated with *Streptococcus salivarius* 57.I (hereafter
348 referred to as strain AGIRA0001), *Streptococcus gordonii* Challis CH1 (AGIRA0002) and *S.*
349 *salivarius* CCHSS3 (strain AGIRA0003). We also investigated an isolate taxonomically
350 affiliated with *Corynebacterium argentoratense* DSM 44202, isolated in parallel with the
351 *Streptococcus* strains. Initial screening of 6 controls and 15 FD patients against these four
352 strains (**Figure 1B**) indicated the presence of bands at ~75-100kDa and ~30-35kDa in 3
353 (50%) controls and 14 (93.3%) FD patients for either AGIRA0001 or AGIRA0003. The
354 presence of any IgG seroreactive banding for either of these *Streptococcus* strains was
355 significantly associated with FD ($\chi^2(5.219, 1), p=0.02$) (**Figure 1C**).

356

357 Given the visual intensity of banding representing an IgG specific interaction between *S.*
358 *salivarius* AGIRA0003 and FD plasma upon screening, we focused on this isolate.
359 Representative immunoblots from total cohort are included in **Figure 1D**. In total, 36
360 (81.8%) FD patients demonstrated a seroreactive response at any molecular weight,
361 compared to 11 (36.7%) controls ($\chi^2(15.7, 1), p<0.0001$) (**Figure 1E**). Within this cohort, 33
362 (75.0%) FD patients had a banding pattern located between 75-100kDa (hereafter referred to
363 as Protein 1), in contrast to 11 (36.7%) of controls ($\chi^2(10.9, 1), p=0.001$) (**Figure 1F**). There
364 was a banding pattern between 30-35kDa (Protein 2) detected in 30 (68.2%) of the FD
365 cohort, compared to 5 (16.7%) of the controls ($\chi^2(19.0, 1), p<0.0001$) (**Figure 1G**). These
366 data validate that there is a significant association between IgG antibodies directed against *S.*
367 *salivarius* AGIRA0003 and FD. The odds ratio of an IgG response at either molecular weight
368 was 7.8 (95% confidence interval, CI 2.6-20.4), for Protein 1 alone was 5.2 (95% CI 1.9-
369 14.1) and Protein 2 alone was 10.7 (95% CI 3.3-29.7). The sensitivity, specificity, positive
370 and negative likelihood ratios, positive and negative predictive values for an IgG seroreactive
371 response at any molecular weight and each protein individually in FD in included in **Table 2**.

372

373 **The seroreactive response to *S. salivarius* AGIRA0003 is not related to symptom sub-**
374 **type, co-morbidities or other immunoglobulin responses.**

375 To ensure the IgG response against *S. salivarius* AGIRA0003 was not the result of a
376 confounding characteristic, the FD cohort was divided by those who had a detectable IgG
377 response (FD IgG⁺, sero-positive) and those who did not (FD IgG⁻, sero-negative).
378 Correlation analysis was performed for both Protein 1 (**Supplementary Table 1**) and Protein
379 2 (**Supplementary Table 2**) bands. There was no difference in IgG status for Protein 1 or 2
380 with regards to *Helicobacter pylori* status, IBS as a co-morbidity, or PPI usage, histamine

381 type 2 receptor agonist (H2RA), or non-steroidal anti-inflammatory drug (NSAIDs) usage.
382 We also screened the serum of 10 Crohn's disease (CD) patients (40.7±13.8 years, 50.0%
383 female) and 9 additional controls (62.2±13.2 years, 44.4% female). There was no significant
384 relationship between the presence of any IgG response (**Supplementary Figure 1**),
385 suggesting this phenomenon may be intrinsic to FD. There was no difference in the presence
386 of IgG antibodies against *Streptococcus salivarius* AGIRA0003 between FD patients with a
387 PDS or EPS±PDS subtype, nor did the IgG response prevalence differ between controls
388 recruited from the community compared to the outpatient population. Finally, there was no
389 difference in IgG seroreactivity between FD and FD with concomitant IBS (**Supplementary**
390 **Figure 2**).

391

392 We also screened a subset of the plasma samples for IgA or IgE antibodies specific to the *S.*
393 *salivarius* AGIRA0003 strain (**Supplementary Figure 3**). Probing of 6 controls and 13 FD
394 patients with IgM identified interactions with bacterial proteins between 50-200kDa in 2
395 (33.33%) controls and 8 (61.54%) FD patients, which were not of statistical significance.
396 There was no significant relationship between IgA seroreactivity against *S. salivarius*
397 AGIRA0003 and FD status and screening for IgE antibodies failed to identify any banding in
398 either group.

399

400 **Identification of candidate seroreactive proteins from *S. salivarius* AGIRA0003**

401 Multiple tryptic peptides recovered from the IgG Protein 1 band were matched with the
402 presumptive “GBS Bsp-repeat domain protein” coding sequence predicted from the
403 PROKKA annotation (loci AGIRA0003_00585; NCBI loci equivalent loci MBW4819708.1)
404 of the AGIRA0003 genome (ExpASY bioinformatics resource portal theoretical molecular
405 weight=85.04kDa, theoretical pI=6.49). Additionally, multiple tryptic peptide masses

406 produced from the Protein 2 band were matched with the presumptive “30S ribosomal
407 subunit S2 protein” predicted from the PROKKA annotation (loci AGIRA0003_01557;
408 NCBI equivalent loci MBW4818971.1) of the AGIRA0003 genome (ExPASy bioinformatics
409 resource portal theoretical molecular weight=28.35kDa, theoretical pI=5.04)
410 **(Supplementary Table 3).**

411

412 **Specific d-MAM species are associated with AGIRA0003 seroreactivity in FD.**

413 We also investigated if there was any link between d-MAM profile (**Supplementary**
414 **Methods**) and the presence or absence of IgG antibodies against *S. salivarius* AGIRA0003 in
415 a subsample irrespective of control/FD status (n=20 total, n=4 IgG⁻, n=16 IgG⁺)
416 **(Supplementary Figure 4)**. There were no statistically significant differences in alpha or
417 beta diversity. Spearman’s correlation revealed positive associations with the presence of IgG
418 antibodies against Protein 1 and the relative abundances of *Salmonella*, *Pseudomonas*,
419 *Microbacterium*, *Leifsonia*, *Klebsiella*, *Gemella*, *Fusobacterium* and *Denitratisoma* spp. in
420 FD but not control. These data suggest that while overall there is not a specific d-MAM
421 profile generated via 16S rRNA amplicon sequencing associated with *S. salivarius*
422 AGIRA0003 reactivity, there are relationships with specific commensal populations.

423

424 **Gut-homing T cells are increased in *S. salivarius* AGIRA0003 reactive FD patients**

425 We investigated if known microinflammatory features we previously reported in a subset of
426 this cohort^{12, 13} were associated with a sero-positive response to the *S. salivarius* AGIRA0003
427 strain. Duodenal eosinophil counts, gut-homing and duodenal effector lymphocyte profiles
428 were available for 15, 12 and 11 outpatient controls; 36, 33 and 33 FD patients respectively.
429 There was no difference in duodenal eosinophil count (**Figure 2A**) and IgG seroreactive
430 status in controls or FD for Protein 1 ($p>0.9$ for all comparisons) (**Figure 2B**), or for Protein

431 2 ($p>0.9$ for all comparisons) (**Figure 2C**). IgG⁺ Protein 1 FD patients had a significantly
432 higher proportion of peripheral CD4⁺ gut-homing T cells, compared to controls (0.33 ± 0.77 vs
433 1.00 ± 1.46 , $p=0.046$) (**Figure 2D,E**). For Protein 2, the proportion of gut-homing T cells was
434 approaching significance in IgG⁺ FD patients compared to controls (0.33 ± 0.77 vs 0.89 ± 1.39 ,
435 $p=0.057$) (**Figure 2F**). There was no difference in duodenal CD4⁺ effector Th2-like or Th17-
436 like cells between seroreactive FD patients or controls (**Supplementary Figure 5**). These
437 data suggest an association between the presence of a seroreactive response to *S. salivarius*
438 AGIRA0003 and increased proportions of gut-homing T cells in FD patients when compared
439 to controls.

440

441 ***S. salivarius* AGIRA0003 disrupts barrier integrity in Caco-2 monolayers and duodenal** 442 **spheroids monolayers**

443 To assess the impact of AGIRA0003 on the small intestinal barrier, Caco-2 cell Transwell
444 monolayers were exposed for 6hrs to *S. salivarius* AGIRA0003, as well as related probiotic
445 M18 and K12 strains (**Figure 3A**). Additionally, ATCC7073 was included as a pro-
446 inflammatory control strain isolated from blood. Barrier integrity was assessed using delta
447 transepithelial electrical resistance (Δ TEER) and was significantly decreased in the LPS
448 group (-110.3 ± 12.5 vs -23.99 ± 7.9 , $p=0.004$) and AGIRA0003 stimulated cells compared to
449 media (-83.9 ± 27.5 , $p=0.046$) (**Figure 3B**). Spot-plating of basolateral media at 3hrs
450 demonstrated greater CFU/mL for AGIRA0003 ($p=0.02$ compared to media) exposed
451 samples in contrast with preparations exposed to the M18, K12 and ATCC7073 strains which
452 were not significant (**Figure 3C**).

453

454 Given tight junction proteins and desmosomes are fundamental to the maintenance of a
455 functional epithelial barrier, we assessed the level of ZO-1, CLDN-1, OCLN, DSC2 and

456 DSG2 (**Figure 3D**). ZO-1 was non-significantly decreased in the *S. salivarius* AGIRA0003
457 group compared to control (0.55 ± 0.03 AGIRA0003, $p=0.058$) and decreased in the
458 ATCC7073-treated cells (0.51 ± 0.05 , $p=0.01$) (**Figure 3E**). CLDN1 was also decreased after
459 exposure to AGIRA0003 compared to control (0.64 ± 0.05 , $p=0.04$) (**Figure 3F**), and
460 proinflammatory control strain ATCC7073 decreased OCLN in Caco-2 cells (0.66 ± 0.08 ,
461 $p=0.04$) (**Figure 3G**). Cleaved DSC2 was decreased in Caco-2 monolayers exposed to
462 ATCC7073 (0.58 ± 0.02 , $p=0.03$) and AGIRA0003 (0.58 ± 0.07 , $p=0.04$) (**Figure 3H**), while
463 DSG2 level was unchanged across all groups (**Figure 3I**). Collectively, these data suggest
464 AGIRA0003 has potential to compromise the epithelial integrity.
465 Given tight junction dysfunction is also repeatedly reported in FD, we examined levels of
466 DSC2, DSG2 and ZO-1 in duodenal biopsies from IgG⁺ FD patients. Immunohistochemical
467 staining demonstrated lower levels of mucosal DSC2 (2.19 ± 0.97 vs 1.49 ± 0.85 , $p=0.02$)
468 (**Figure 4A**) and DSG2 (23.22 ± 15.92 vs 12.38 ± 7.34 , $p=0.04$) in IgG⁺ FD compared to
469 controls (**Figure 4B**). ZO-1 was not significantly changed in IgG⁺ FD compared to control
470 (32.96 ± 19.30 vs 22.77 ± 11.10 , $p=0.08$) (**Figure 4C**). A reduction in mucosal DSG2 in FD
471 patients IgG⁺ for Protein 2 was the only difference between IgG⁺ and IgG⁻ FD (21.6 ± 15.1 vs
472 10.1 ± 6.2 , $p=0.04$) for any of the 3 targets (**Supplementary Figure 6**).

473

474 We next exposed duodenal spheroids from FD patients with IgG seroreactivity (n=4) to
475 AGIRA0003 for 6 hours and assessed tight junction and desmosomal protein levels by
476 immunoblot (**Figure 5A**). While ZO-1 was unchanged in spheroids exposed to AGIRA0003
477 (**Figure 5B**), DSG2 was decreased following AGIRA0003 exposure compared to both media
478 (0.30 ± 0.12 , $p=0.03$) and LPS (0.99 ± 0.10 , $p=0.03$) (**Figure 5C**). CLDN1 was also decreased
479 after AGIRA0003 exposure compared to media alone (0.49 ± 0.11 , $p=0.03$) and LPS
480 (0.76 ± 0.23 , $p=0.03$) (**Figure 5D**). We also observed a reduction in DSC2 after AGIRA0003

481 exposure compared to media (0.64 ± 0.33 , $p=0.03$) (**Figure 5E**). Collectively, these findings
482 suggest that *S. salivarius* AGIRA0003 actively impairs duodenal barrier defences.

483

484 ***S. salivarius* AGIRA0003 may have virulent capacity based on genome interrogation.**

485 Given we demonstrated the capacity of *S. salivarius* AGIRA0003 to impact tight junction
486 integrity, we investigated potential pathogenic capacity through *in silico* analysis.

487 Comparative genomics identified 81 unique AGIRA0003 genes when aligned to the probiotic
488 M18 and K12 strains that did not disrupt tight junctions (**Supplementary Table 4**). Within

489 this list of singletons, 4 genes with virulent properties (e.g., LPS, flagella, pilus, toxins)²³

490 were annotated as type II toxin-antitoxin system death-on-curing family toxin, FliM/FliN

491 family flagellar motor switch protein/ type III secretion system (T3SS) cytoplasmic ring

492 protein SctQ [from *Lysobacter enzymogenes*], O-antigen ligase family protein [*Lysobacter*

493 sp. K5869] and sigma 54-interacting transcriptional regulator/type 4 pilus PilR [*Lysobacter*

494 *enzymogenes*].

495 **DISCUSSION**

496 In this study, we demonstrate the presence of IgG antibodies in FD patient plasma directed
497 against proteins from *S. salivarius* AGIRA0003, a novel isolate from the FD duodenum¹⁵,
498 suggesting that *S. salivarius* AGIRA0003 is a pathobiont in the FD mucosal
499 microenvironment. Further, IgG⁺ FD patients had significantly higher circulating gut-homing
500 T cells and these cells have been previously associated with intensity of pain, cramping,
501 nausea and vomiting in FD²⁴. Additionally, we show *S. salivarius* AGIRA0003 has capacity
502 to disrupt tight junctions and desmosomes in both polarised Caco-2 cells and FD patient-
503 derived duodenal spheroids. These disruptions are mirrored in the pathology of FD patients,
504 suggesting a potential mechanism for a host-microbe interaction that results in the generation
505 of the observed immune response.

506

507 Approximately 10% of FD cases are thought to have a post-infectious aetiology (PI-FD)
508 arising from an acute GI infection²⁵. PI-FD is associated with more severe symptoms,
509 including more weight loss, nausea, vomiting and early satiety²⁶, and higher incidence of co-
510 morbid insomnia, depression and anxiety²⁷ than non-PI-FD. However, it is likely the true
511 prevalence of PI-FD is higher, given the diagnostic reliance on patient recall of infection in
512 the general population. In support of this, anti-cytolethal distending toxin (CtdB) antibodies,
513 produced in response to infection by Gram negative bacteria²⁸ are increased in FD and other
514 DGBI patient serum compared to controls²⁹⁻³¹. DGBI patients also have elevated anti-
515 vinculin antibodies, believed to result from cross reactivity between anti-CtdB antibodies and
516 vinculin proteins³², collectively supporting a role for infection in FD onset.

517

518 Sequence comparison identified cell wall associated tandem repeats (GBS Bsp-like repeat
519 protein) and a ribosome associated protein (30S ribosomal protein S2) as the likely

520 seroreactive candidates. The ribosomal subunit is important for binding of transfer RNA and
521 messenger RNA during translation³³. The GBS Bsp-like repeat proteins are implicated in
522 colonisation and interactions of microbes with epithelial cells³⁴, including heightened
523 virulence of related *Streptococcus* spp. for competitive advantage in mucosal infections³⁵.
524 This GBS Bsp-like repeat protein exists in a tandem repeat sequence in our isolate, in close
525 proximity to a GH25 muramidase catalytic module (AtIA). This is an autolysin of Gram-
526 positive bacteria that hydrolyses 1,4-beta linkages between N-acetylmuramic acid and N-
527 acetyl-D-glucosamine residues to degrade bacterial cell walls³⁶. When this protein was
528 overexpressed in Group B *Streptococcus* spp., the cellular morphology was observed to
529 become more elongated and lens-shaped, rather than spherical³⁷, suggesting that Bsp-like
530 repeat proteins play a role in mediating cellular morphology, and by extension, evading host
531 detection and enabling mucosal colonisation^{35, 38}.

532 Tight junction proteins are integral in forming the intestinal epithelial barrier and inhibiting
533 the translocation of mucosal antigens through the paracellular space to the lamina propria.
534 Given that our cell culture data demonstrates the capacity of *S. salivarius* AGIRA0003, but
535 not the related probiotic strains we assessed, to translocate through intestinal monolayers
536 while reducing tight junction and desmosome protein levels in both Caco-2 and FD-derived
537 spheroids, this may represent a pathway for immune sensitisation and activation in FD. Many
538 entero-pathogens, have adapted to target or disorganise tight junction proteins to allow for
539 epithelial translocation via virulence proteins³⁹. Comparative genomics analysis of the *S.*
540 *salivarius* AGIRA0003 genome identified 4 unique genes with potential virulence. Of
541 particular interest was the FliM/FliN family flagellar motor switch protein/Type 3 secretor
542 system (T3SS) cytoplasmic ring protein SctQ. The T3SS is a transmembrane complex that
543 enables protein transport into host cells and is a feature of highly pathogenic bacteria
544 including *Enterococcus*, *Shigella*, *Vibrio*, *Salmonella* and *Pseudomonas*⁴⁰. This complex is

545 integral to the capacity of such enteropathogens in targeting tight junction proteins^{41, 42}. The
546 Walkerton, Ontario, Canada outbreak of acute gastroenteritis, due to T3SS complex and/or
547 FliM/FliN proteins^{43, 44} positive *Escherichia coli* 0157:H7 and *Campylobacter* spp.⁴⁵⁻⁴⁷,
548 resulted in a higher prevalence of PI-FD up to 8-years post outbreak in those who contracted
549 gastroenteritis⁴⁵. While the complete secretion system was not encoded in the *S. salivarius*
550 AGIRA0003 genome, if functionally expressed, this protein may act as an antigenic stimulant
551 of the host response in patients with previous history of infection with other bacterium
552 utilising this system, potentially contributing to the onset of PI-FD.

553

554 Desmosomes (including DSC2, DSG2) are junctions critical for strong adhesion and linking
555 cytoskeletal filaments to cell-cell contact sites, and as such, disruption to these proteins
556 weakens the epithelial monolayer, a feature leveraged by some pathogens with capacity to
557 disassemble desmosomes⁴⁸. For example, proteolytic cleavage of desmoglein proteins by *S.*
558 *pyogenes* has been associated with impaired epidermal barrier and the development of
559 cutaneous infection⁴⁹. Further, DSC2 is targeted by *Giardia duodenalis*⁵⁰ and loss of DSG2
560 has been implicated in Crohn's disease⁵¹. Reduction in DSC2 and DSG2 gene expression⁵²,
561 and DSG2 protein levels¹¹ have been shown in duodenal biopsies from FD patients compared
562 to controls. As such, our findings proposition *S. salivarius* AGIRA0003 as a FD pathobiont
563 capable of disassembling desmosomes and tight junction proteins. This may represent a
564 microbial driven mechanism for the reduced barrier integrity in FD patients that would then
565 permit increased interaction of luminal contents with the host immune system.

566

567 While we have shown that *S. salivarius* AGIRA0003 drives barrier dysfunction and that IgG
568 seroreactivity is associated with gut homing T cells, a larger study (incorporating a known
569 and unselected validation cohort) across multiple international sites is required to

570 conclusively establish *S. salivarius* AGIRA0003 as a causative agent and biomarker for FD.
571 Nevertheless, our cohort was recruited from three sites across New South Wales, Australia
572 spanning well over a 100km radius. Further, we have shown that AGIRA003 seroreactivity is
573 not associated with Crohn’s disease, where patients exhibit barrier dysfunction nor outpatient
574 controls. While biomarkers including zonulin, anti-CtdB, and anti-vinculin antibodies have
575 been proposed to distinguish DGBIs^{29, 30, 53, 54}, their translation into standard care is impeded
576 by heterogeneity and marker overlap with other diseases/physiological states⁵⁵. Thus, a larger
577 validation cohort may provide utility for *S. salivarius* AGIRA0003 as a diagnostic marker
578 discriminating FD from other conditions (including inflammatory bowel diseases and coeliac
579 disease). A further limitation is the lack of data on the absolute abundance of *S. salivarius*
580 AGIRA0003 globally, as most data assessing small intestinal mucosal sites has utilised 16S
581 RNA gene amplicon sequencing , which does not allow for strain level identification⁵⁶ and
582 cost and difficulty removing host DNA from duodenal samples limits shotgun metagenomics.
583 To that end, progress has been made with capturing and characterising the MAM by
584 “culturomics’ a novel combination of microbe culture with metagenomic sequencing⁵⁷. Here,
585 our findings show that microbe cultivation also represents a meaningful and feasible
586 alternative to functionally examine the d-MAM, beyond the widely practised “culture-
587 independent” methods. Investigation of the prevalence of this strain in other intestinal niches,
588 in addition to the duodenum, will facilitate further understanding of its role in FD
589 pathophysiology.

590

591 We have provided evidence of a dysregulated relationship between the novel duodenal *S.*
592 *salivarius* strain AGIRA0003 and the host immune system in FD. Relationships between GI
593 disease and immune responses involving the commensal microbiota have been previously
594 reported, although to our knowledge, ours is the first study to identify seroreactivity to a

595 specific bacterium in the blood of FD patients. Our comparative genomic analysis of other *S.*
596 *salivarius* strains demonstrated that *S. salivarius* AGIRA0003 contains unique genes
597 putatively implicated with virulence and we have functionally highlighted the capacity of this
598 strain to reduce barrier integrity via disruption of tight junction and desmosome proteins.
599 Importantly, our data show that duodenal pathobionts can cause the epithelial dysfunction
600 previously identified in FD¹¹ and that immunoreactivity to pathobionts can explain the
601 immunological features of FD^{13,24}. Overall, our findings suggest *S. salivarius* AGIRA0003 is
602 a novel pathobiont that may contribute to FD pathogenesis, and thereby represent a potential
603 biomarker and therapeutic target.

604 **References**

605

- 606 1. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology,
607 Clinical Features and Rome IV. *Gastroenterology* 2016;150:1262-1279.e2.
- 608 2. Shah A, Fairlie T, Brown G, et al. Duodenal Eosinophils and Mast Cells in Functional
609 Dyspepsia: A Systematic Review and Meta-Analysis of Case-Control Studies. *Clin*
610 *Gastroenterol Hepatol* 2022;20:2229-2242 e29.
- 611 3. Ji R, Wang P, Kou GJ, et al. Impaired gastric mucosal integrity identified by confocal
612 endomicroscopy in *Helicobacter pylori*-negative functional dyspepsia.
613 *Neurogastroenterology and Motility* 2020;32:e13719.
- 614 4. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel
615 disorders: a Rome foundation report. *Gut* 2013;62:159-76.
- 616 5. Chey WD. The Role of Food in the Functional Gastrointestinal Disorders:
617 Introduction to a Manuscript Series. *Am J Gastroenterol* 2013;108:694-697.
- 618 6. Schulz O, Pabst O. Antigen sampling in the small intestine. *Trends Immunol*
619 2013;34:155-61.
- 620 7. Shanahan ER, Kang S, Staudacher H, et al. Alterations to the duodenal microbiota are
621 linked to gastric emptying and symptoms in functional dyspepsia. *Gut* 2023;72:929-
622 938.
- 623 8. Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on
624 the small intestine. *Gut* 2017;66:1168-1169.
- 625 9. Fukui A, Takagi T, Naito Y, et al. Higher Levels of *Streptococcus* in Upper
626 Gastrointestinal Mucosa Associated with Symptoms in Patients with Functional
627 Dyspepsia. *Digestion* 2020;101:38-45.
- 628 10. Shanahan ER, Zhong L, Talley NJ, et al. Characterisation of the gastrointestinal
629 mucosa-associated microbiota: a novel technique to prevent cross-contamination
630 during endoscopic procedures. *Aliment Pharmacol Ther* 2016;43:1186-96.
- 631 11. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and
632 low-grade inflammation in functional dyspepsia. *Gut* 2014;63:262-71.
- 633 12. Burns G, Carroll G, Mathe A, et al. Evidence for Local and Systemic Immune
634 Activation in Functional Dyspepsia and the Irritable Bowel Syndrome: A Systematic
635 Review. *Am J Gastroenterol* 2019;114:429-436.
- 636 13. Burns GL, Bruce JK, Minahan K, et al. Type 2 and type 17 effector cells are
637 increased in the duodenal mucosa but not peripheral blood of patients with functional
638 dyspepsia. *Front Immunol* 2023;13:1051632.
- 639 14. Bruce JK, Burns GL, Sinn Soh W, et al. Defects in NLRP6, autophagy and goblet cell
640 homeostasis are associated with reduced duodenal CRH receptor 2 expression in
641 patients with functional dyspepsia. *Brain Behav Immun* 2022;101:335-345.
- 642 15. Hoedt EC, Shanahan ER, Keely S, et al. Draft Genome Sequence of *Streptococcus*
643 *salivarius* AGIRA0003, Isolated from Functional Gastrointestinal Disorder Duodenal
644 Tissue. *Microbiol Resour Announc* 2021;10:e0075821.
- 645 16. Balch WE, Fox GE, Magrum LJ, et al. Methanogens: reevaluation of a unique
646 biological group. *Microbiological Reviews* 1979;43:260-296.
- 647 17. Lodes MJ, Cong YZ, Elson CO, et al. Bacterial flagellin is a dominant antigen in
648 Crohn disease. *Journal of Clinical Investigation* 2004;113:1296-1306.
- 649 18. Shevchenko A, Tomas H, Havlis J, et al. In-gel digestion for mass spectrometric
650 characterization of proteins and proteomes. *Nat Protoc* 2006;1:2856-60.
- 651 19. Keely S, Ryan SM, Haddleton DM, et al. Dexamethasone-pDMAEMA polymeric
652 conjugates reduce inflammatory biomarkers in human intestinal epithelial
653 monolayers. *Journal of Controlled Release* 2009;135:35-43.

- 654 20. Bolan S, Seshadri B, Keely S, et al. Bioavailability of arsenic, cadmium, lead and
655 mercury as measured by intestinal permeability. *Scientific Reports* 2021;11.
- 656 21. Bruce J, Kaiko GE, Keely S. Isolation and In Vitro Culture of Human Gut Progenitor
657 Cells. In: Joglekar MV, Hardikar AA, eds. *Progenitor Cells: Methods and Protocols*.
658 New York, NY: Springer New York, 2019:49-62.
- 659 22. Dieckmann Marius A, Beyvers S, Nkouamedjo-Fankep Rudel C, et al. EDGAR3.0:
660 comparative genomics and phylogenomics on a scalable infrastructure. *Nucleic Acids
661 Research* 2021;49:W185-W192.
- 662 23. Liu B, Zheng D, Zhou S, et al. VFDB 2022: a general classification scheme for
663 bacterial virulence factors. *Nucleic Acids Research* 2021;50:D912-D917.
- 664 24. Liebrechts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated
665 with symptoms and delayed gastric emptying in functional dyspepsia. *Am J
666 Gastroenterol* 2011;106:1089-98.
- 667 25. Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-
668 infectious functional dyspepsia. *Aliment Pharmacol Ther* 2015;41:177-88.
- 669 26. Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics
670 of acute-onset functional dyspepsia. *Gastroenterology* 2002;122:1738-47.
- 671 27. Tuteja AK, Talley NJ, Stoddard GJ, et al. Risk factors for upper and lower functional
672 gastrointestinal disorders in Persian Gulf War Veterans during and post deployment.
673 *Neurogastroenterology & Motility* 2019;31:e13533.
- 674 28. Mortensen NP, Schiellerup P, Boisen N, et al. The role of *Campylobacter jejuni*
675 cytolethal distending toxin in gastroenteritis: toxin detection, antibody production,
676 and clinical outcome. *APMIS* 2011;119:626-34.
- 677 29. Talley NJ, Holtmann G, Walker MM, et al. Circulating Anti-cytolethal Distending
678 Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare
679 Populations With Functional Dyspepsia and Irritable Bowel Syndrome. *Clin Transl
680 Gastroenterol* 2019;10:e00064.
- 681 30. Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker
682 for diarrhea-predominant irritable bowel syndrome in human subjects. *PLoS One*
683 2015;10:e0126438.
- 684 31. Rezaie A, Park SC, Morales W, et al. Assessment of Anti-vinculin and Anti-
685 cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
686 *Dig Dis Sci* 2017;62:1480-1485.
- 687 32. Pimentel M, Morales W, Pokkunuri V, et al. Autoimmunity Links Vinculin to the
688 Pathophysiology of Chronic Functional Bowel Changes Following *Campylobacter*
689 *jejuni* Infection in a Rat Model. *Dig Dis Sci* 2015;60:1195-205.
- 690 33. Thompson JF, Hearst JE. Structure-function relations in *E. coli* 16S RNA. *Cell*
691 1983;33:19-24.
- 692 34. Rego S, Heal TJ, Pidwill GR, et al. Structural and Functional Analysis of Cell Wall-
693 anchored Polypeptide Adhesin BspA in *Streptococcus agalactiae*. *J Biol Chem*
694 2016;291:15985-6000.
- 695 35. Rego S, Heal TJ, Pidwill GR, et al. Structural and Functional Analysis of Cell Wall-
696 anchored Polypeptide Adhesin BspA in *Streptococcus agalactiae*. *Journal of
697 Biological Chemistry* 2016;291:15985-16000.
- 698 36. Ahn SJ, Burne RA. The *atIA* operon of *Streptococcus mutans*: role in autolysin
699 maturation and cell surface biogenesis. *J Bacteriol* 2006;188:6877-88.
- 700 37. Reinscheid DJ, Stosser C, Ehlert K, et al. Influence of proteins Bsp and FemH on cell
701 shape and peptidoglycan composition in group B streptococcus. *Microbiology
702 (Reading)* 2002;148:3245-3254.

- 703 38. Manzer HS, Nguyen DT, Park JY, et al. The Group B Streptococcal Adhesin BspC
704 Interacts with Host Cytokeratin 19 To Promote Colonization of the Female
705 Reproductive Tract. *mBio* 2022;13:e01781-22.
- 706 39. Tafazoli F, Holmstrom M A, Forsberg J, et al. Apically Exposed, Tight Junction-
707 Associated β 1-Integrins Allow Binding and YopE-Mediated Perturbation of Epithelial
708 Barriers by Wild-Type *Yersinia* Bacteria. *Infection and Immunity* 2000;68:5335-
709 5343.
- 710 40. Notti RQ, Stebbins CE. The Structure and Function of Type III Secretion Systems.
711 *Microbiol Spectr* 2016;4.
- 712 41. Ugalde-Silva P, Gonzalez-Lugo O, Navarro-Garcia F. Tight Junction Disruption
713 Induced by Type 3 Secretion System Effectors Injected by Enteropathogenic and
714 Enterohemorrhagic *Escherichia coli*. *Frontiers in Cellular and Infection Microbiology*
715 2016;6.
- 716 42. Coburn B, Sekirov I, Finlay BB. Type III Secretion Systems and Disease. *Clinical*
717 *Microbiology Reviews* 2007;20:535-549.
- 718 43. Ideses D, Gophna U, Paitan Y, et al. A Degenerate Type III Secretion System from
719 Septicemic *Escherichia coli* Contributes to Pathogenesis. *Journal of Bacteriology*
720 2005;187:8164-8171.
- 721 44. Gabbert AD, Mydosh JL, Talukdar PK, et al. The Missing Pieces: The Role of
722 Secretion Systems in *Campylobacter jejuni* Virulence. *Biomolecules* 2023;13:135.
- 723 45. Ford AC, Thabane M, Collins SM, et al. Prevalence of Uninvestigated Dyspepsia 8
724 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study.
725 *Gastroenterology* 2010;138:1727-1736.
- 726 46. Garg A, Macnab J, Clark W, et al. Long-term Health Sequelae Following *E.coli* and
727 *Campylobacter* Contamination of Municipal Water. *Canadian Journal of Public*
728 *Health* 2005;96:125-130.
- 729 47. Garg AX, Marshall J, Salvadori M, et al. A gradient of acute gastroenteritis was
730 characterized, to assess risk of long-term health sequelae after drinking bacterial-
731 contaminated water. *Journal of Clinical Epidemiology* 2006;59:421-428.
- 732 48. Roxas JL, Vedantam G, Viswanathan VK. Epithelial maturity influences EPEC-
733 induced desmosomal alterations. *Gut Microbes* 2019;10:241-245.
- 734 49. Sumitomo T, Mori Y, Nakamura Y, et al. Streptococcal Cysteine Protease-Mediated
735 Cleavage of Desmogleins Is Involved in the Pathogenesis of Cutaneous Infection.
736 *Frontiers in Cellular and Infection Microbiology* 2018;8.
- 737 50. Maia-Brigagão C, Morgado-Díaz JA, De Souza W. Giardia disrupts the arrangement
738 of tight, adherens and desmosomal junction proteins of intestinal cells. *Parasitology*
739 *International* 2012;61:280-287.
- 740 51. Spindler V, Meir M, Vigh B, et al. Loss of Desmoglein 2 Contributes to the
741 Pathogenesis of Crohn's Disease. *Inflammatory Bowel Diseases* 2015;21:2349-2359.
- 742 52. Puthanmadhom Narayanan S, O'Brien DR, Sharma M, et al. Duodenal Mucosal
743 Barrier in Functional Dyspepsia. *Clinical Gastroenterology and Hepatology*
744 2022;20:1019-1028.e3.
- 745 53. Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for
746 irritable bowel syndrome. *Aliment Pharmacol Ther* 2009;29:834-42.
- 747 54. Talley NJ, Holtmann GJ, Jones M, et al. Zonulin in serum as a biomarker fails to
748 identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity. *Gut*
749 2020;69:1-3.
- 750 55. Ohlsson B, Orho-Melander M, Nilsson PM. Higher Levels of Serum Zonulin May
751 Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with
752 Gastrointestinal Symptoms or Disease Manifestations. *Int J Mol Sci* 2017;18:582.

- 753 56. Brown G, Hoedt EC, Keely S, et al. Role of the duodenal microbiota in functional
754 dyspepsia. *Neurogastroenterology & Motility* 2022;34.
- 755 57. Teh JJ, Berendsen EM, Hoedt EC, et al. Novel strain-level resolution of Crohn's
756 disease mucosa-associated microbiota via an ex vivo combination of microbe culture
757 and metagenomic sequencing. *The ISME Journal* 2021.
- 758

FIGURE LEGENDS

Figure 1: Screening of patient plasma for IgG antibodies against *Streptococcus salivarius* AGIRA0003.

Total protein extracted from novel duodenal bacterial lysates was electrophoresed and (A) immunoblotted with patient plasma as the probing antibody to determine interactions between the duodenal microbiota and patient plasma. Figure created with BioRender.com. (B) Representative immunoblots of this screening process, where 1= *Streptococcus salivarius* strain AGIRA0001, 2= *Streptococcus gordonii* AGIRA0002, 3= *Streptococcus salivarius* strain AGIRA0003, 4= *Corynebacterium argenteum*. (C) The presence of an interaction with either *Streptococcus salivarius* strain AGIRA0001 or AGIRA0003 was tested for potential associations with FD in the screening population. n=6 controls n=15 FD. The presence of AGIRA0003 IgG seroreactivity in the total cohort was then investigated. (D) Banding patterns observed in immunoblots where total protein extracted from the bacteria was probed with patient or control plasma. (E) The number of FD patients demonstrating a seroreactive response at any molecular weight was compared to seroreactive controls. The number of FD patients with a banding pattern located (F) between 75-100kDa (Protein 1) and (G) between 30-35kDa (Protein 2) compared to the number of positive controls to determine if there was a relationship between this reaction and FD. n=17 controls, n=40 FD patients. Statistical analysis, Chi-square test, * $p < 0.05$ *** $p < 0.001$ **** $p < 0.0001$.

Figure 2: IgG seroreactive status, eosinophils and gut-homing T cells in FD patients.

(A) Eosinophils in haematoxylin and eosin-stained biopsies from a subset of the cohort were enumerated as part of a previous study. Scale bar = 50um, yellow arrows identify example eosinophils. Eosinophil numbers were compared between controls, IgG⁺ and IgG⁻ FD patients for (B) Protein 1 and (C) Protein 2 (D) Flow cytometry was used to examine gut-homing

CD4⁺ cell populations in controls and FD patients in a previous study. These populations were examined in IgG⁺ and IgG⁻ FD patients for (E) Protein 1 and (F) Protein 2. (B,C) n=15 controls, n=36 FD (E,F) n=12 controls, n=33 FD. Data presented as mean±SEM. Statistical analysis: Kruskal-Wallis test, **p*<0.05.

Figure 3: Tight junction proteins following exposure of Caco-2 cells to *S. salivarius* AGIRA0003, M18, K12 and ATCC7073 strains.

(A) Caco-2 Transwell monolayers were stimulated for 6hrs with either media only, 1µg/mL LPS, or *S. salivarius* AGIRA0003, M18, K12 and ATCC7073 strains in triplicate. Figure created with BioRender.com. (B) The difference in TEER values ($\Omega \times \text{cm}^2$) of monolayers pre and post 6-hour challenge. (C) Bacterial translocation across the Transwell was assessed by spot-plating from basolateral media at 3 hours post-stimulation and counting resulting colonies. (D) Protein was extracted from Caco-2 cells post-stimulation and tight junction associated proteins (E) ZO-1, (F) CLDN1, (G) OCLN, (H) DSC2 and (I) DSG2 were assessed by immunoblot as fold change to media. Data presented as mean±SEM. Statistical analysis: non-parametric ANOVA with Dunn's correction. **p*<0.05, ***p*<0.01.

Figure 4: Tight junction associated proteins, DSC2, DSG, and ZO-1, in duodenal biopsies from IgG⁺ FD patients.

Formalin fixed, paraffin embedded duodenal biopsies from IgG⁺ FD patients compared to outpatient controls were immunohistochemically stained and H score quantified for (A) DSC2, (B) DSG2 and (C) ZO-1. n=13 controls, n=17 FD. Scale bar = 50µM. Top row=10x magnification, bottom=40x. Statistical analysis: (A) non-parametric t test, (B, C) parametric t test. **p*<0.05.

Figure 5: Tight junction proteins following exposure of FD patient-derived duodenal spheroids to *S. salivarius* AGIRA0003.

(A) FD patient-derived duodenal spheroids (n=4 lines) were stimulated for 6hrs with either media, 1µg/mL LPS, or *S. salivarius* AGIRA0003 in triplicate. Figure created with BioRender.com. Protein was extracted from the cells at 6 hours post-stimulation and tight junction associated proteins (B) ZO-1, (C) DSG2 (D) CLDN1 and (E) DSC2 were assessed by immunoblot. Data presented as mean±SEM, fold change to 1 (media). Statistical analysis: paired non-parametric ANOVA. * $p < 0.05$. M=media only, L=LPS stimulation, A=AGIRA0003 stimulation.

Table 1: Demographic and clinical characteristics of study cohort





| | Controls | FD | p value |
|--|-----------------|---------------|----------------|
| | n=30 | n=44 | |
| Age (mean±SD) | 48.87 (15.66) | 46.59 (17.46) | 0.57 |
| Female (%) | 19 (63.33) | 35 (79.55) | 0.18 |
| BMI (mean±SD) | 28.16 (5.80) | 26.93 (5.70) | 0.28 |
| PPI use (%)# | 3 (10.71) | 13 (40.63) | 0.02* |
| H2RA use (%)# | 0 | 4 (12.50) | 0.12 |
| NSAIDS use (%)# | 2 (7.14) | 3 (9.38) | >0.99 |
| Helicobacter pylori positive (%)# | 2 (18.18) | 1 (3.57) | 0.187 |
| IBS co-morbidity (%)# | 1 (3.33) | 17 (38.64) | 0.001** |

denotes a factor that was not provided by all participants included in this cohort
BMI = body mass index, PPI = proton pump inhibitor, H2RA = H2 receptor antagonist, NSAIDS = non-steroidal anti-inflammatory drugs, IBS = irritable bowel syndrome





Table 2: Sensitivity and specificity for IgG antibodies against *Streptococcus salivarius* AGIRA0003 as a marker of FD.

| | IgG seroreactivity (95% CI) | IgG seroreactivity (Protein 1 only) (95% CI) | IgG seroreactivity (Protein 2 only) (95% CI) |
|---------------------------|--|---|---|
| Sensitivity | 81.82% (68.04 – 90.49) | 75.00% (60.56 – 85.43) | 68.18% (53.44 – 80.00) |
| Specificity | 63.33% (45.51 – 78.13) | 63.33% (45.51– 78.13) | 83.33% (66.44 – 92.66) |
| Positive Likelihood Ratio | 2.23 (1.37 - 3.64) | 2.05 (1.24 – 3.37) | 4.09 (1.79 – 9.34) |
| Negative Likelihood Ratio | 0.29 (0.14 - 0.57) | 0.39 (0.22 – 0.70) | 0.38 (0.24 – 0.61) |
| Positive Predictive Value | 76.60% (62.78 – 86.40) | 75.00% (60.56 – 85.43) | 85.71% (70.62 – 93.74) |
| Negative Predictive Value | 70.37% (51.52 – 84.15) | 63.33% (45.51 – 78.13) | 64.10% (48.42 – 77.26) |
| Odds Ratio | 7.77 (2.64 – 20.39) | 5.18 (1.92 – 14.13) | 10.71 (3.34 – 29.70) |

Wilson/Brown method for 95% confidence interval (CI).



IgG - Representative of total population screening



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.15.24310426>; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

